|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
Why scented candles could cause cancer [The Telegraph]
|
|
|
|
|
|
A
study carried out by Professor Alastair Lewis of the National Centre
for Atmospheric Science at the University of York found that an
ingredient commonly used to give candles their scent mutates into
formaldehyde upon contact with the air.
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.2 Pharma
|
|
|
Two drug makers engage in a murky battle over the use of the Merck name [STAT]
|
|
|
|
|
|
What’s
in a name?Plenty, especially if you happen to run a company called
Merck. In fact, there are two drug makers with that moniker. One is
based in the United States and the other is headquartered in Germany,
but is formally known as Merck KGgA. And not surprisingly, they are
warring over use of the name — again.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
FDA delays decision on Heron's nausea drug [Reuters]
|
|
|
|
|
|
Heron
Therapeutics Inc said the U.S. Food and Drug Administration had
postponed a decision on its injectable drug to treat
chemotherapy-induced nausea. The FDA is now expected to decide on Sustol
by late February instead of the earlier deadline of Sunday.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.5 ASCO
|
|
|
|
Everolimus Slows Growth of Neuroendocrine Tumors [ASCO]
|
|
|
|
|
|
Researchers
report the results of a new analysis from a phase III trial of patients
with neuroendocrine tumors that begin in the gastrointestinal (GI)
tract or have an unknown origin. Compared to placebo, everolimus was
associated with a six- to eight-month longer time period before the
cancer worsened.
|
|
|
|
|
|
|
New Targeted Hormone-Radiation Treatment Slows Growth of Midgut Neuroendocrine Tumors [ASCO]
|
|
|
|
|
|
According
to the authors, this is the first prospective, randomized trial to
evaluate the efficacy of 177Lutetium-DOTATATE in patients with advanced
midgut neuroendocrine tumors. All 230 trial participants had advanced
tumors that worsened despite first-line somatostatin analog therapy. The
patients were randomly assigned to treatment with 177Lutetium-DOTATATE
or high-dose octreotide LAR.
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.10 Politiques
|
|
|
Moonshot, They Say [In the Pipeline]
|
|
|
|
|
|
Gitlin’s
right: we don’t need another big, flashy initiative, no matter how nice
it sounds. We need steady, sustained work in this area, which means
steady funding, and not yanking people around to serve on committees to
see how to get some of the fast cash, which will disappear, anyway.
|
|
|
|
|
|
|
|
|
ASCO Official Participates in Vice President’s “Moonshot” Launch [ASCO]
|
|
|
|
|
|
In
meetings and interactions with Biden's office leading up today’s
launch, ASCO stressed the need to widely implement “big data”
initiatives, such as ASCO’s CancerLinQ rapid-learning system, for the
immediate benefit of current patients and long-term benefit of patients
around the world for generations to come.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
NIH’s big cancer database coming soon [Washington Post]
|
|
|
|
|
|
When
it launches this summer, the Genomic Data Commons will be able to hold
data from as many as 50,000 patients and clinical trial participants,
including genomic analysis of their cancers, the treatments used, their
responses and outcomes, Lowy said. The information would come not just
from NCI clinical trials but from other research as well.
|
|
|
|